The XenoMouse That Roared: Cell Genesys' Share Of Abgenix Worth $781 Mil.
Cell Genesys' 12% share of Abgenix at the end of February is worth more than twice the value of Genzyme's attempted acquisition of Cell Genesys in October.
You may also be interested in...
Novartis' cancellation of several outsourcing contracts with Parexel could result in a reduction of the contract research organization's workforce by 400-500 positions, Parexel said.
Amgen is reclaiming its biotech identity as Wall Street rushes back to biotechnology.
Cell Genesys spin-off Abgenix' success in marketing its XenoMouse technology has helped terminate a proposed merger between Genzyme and Cell Genesys.